Influenza;
influenza vaccination;
high dose influenza vaccine;
cost-effectiveness;
cost-utility analysis;
quadrivalent influenza vaccine;
France;
I:;
Health;
Education;
and Welfare;
I11: Analysis of Health Care Markets;
I18: Government Policy;
Regulation;
Public Health;
DOUBLE-BLIND;
EFFICACY;
D O I:
10.1080/13696998.2024.2404331
中图分类号:
F [经济];
学科分类号:
02 ;
摘要:
BackgroundSeasonal influenza outbreaks in France cause a surge in patients, exacerbating the overburdened healthcare system each winter. Older adults are particularly vulnerable to serious events related to influenza. Quadrivalent influenza high dose (QIV HD) vaccines have been developed to offer better clinical protection in older adults, who often exhibit suboptimal immune response to quadrivalent influenza standard dose vaccines (QIV SD). This study aims to evaluate the public health impact and cost-effectiveness of administering HD versus SD vaccines to individuals aged 65+ in France. MethodologyUsing a static model and decision-tree approach, the study analyzed health outcomes such as influenza cases, GP (general practitioner) visits, hospitalizations, and mortality; relative vaccine efficacy (rVE) estimates were derived from a pivotal randomized-controlled trial and a meta-analysis comparing HD to SD vaccines. Two approaches were implemented to model hospitalizations (conditional on influenza or not), and analyses on bed occupancy were performed. ResultsResults showed that using QIV HD instead of QIV SD during an average influenza season in France led to the prevention of 57,209 additional cases of influenza, 13,704 GP visits, and 764 influenza-related deaths. Moreover, switching to QIV HD resulted in an additional 1,728-15,970 hospitalizations avoided and 15,124-138,367 reduced days of hospitalization depending on the hospitalization approach used. The cost-utility analysis showed a cost per quality-adjusted life year (QALY) gained ranging from 24,020 <euro>/QALY to 5,036 <euro>/QALY. ConclusionsSwitching to QIV HD in older adults was shown to be cost-effective, with even greater public health benefits at a higher coverage rate, regardless of the season severity.
机构:
Univ Rennes, Dept Quantitat Methods Publ Hlth, UPRES EA Reperes 7449, EHESP, 15 Av Prof, F-35043 Rennes, FranceUniv Rennes, Dept Quantitat Methods Publ Hlth, UPRES EA Reperes 7449, EHESP, 15 Av Prof, F-35043 Rennes, France
Crepey, Pascal
Boiron, Louis
论文数: 0引用数: 0
h-index: 0
机构:
Sanofi Pasteur, Av Nacoes Unidas,14410 Condominio Parque, BR-04794000 Sao Paulo, SP, BrazilUniv Rennes, Dept Quantitat Methods Publ Hlth, UPRES EA Reperes 7449, EHESP, 15 Av Prof, F-35043 Rennes, France
Boiron, Louis
Araujo, Rafael Rodrigo
论文数: 0引用数: 0
h-index: 0
机构:
Sanofi Pasteur, Av Nacoes Unidas,14410 Condominio Parque, BR-04794000 Sao Paulo, SP, BrazilUniv Rennes, Dept Quantitat Methods Publ Hlth, UPRES EA Reperes 7449, EHESP, 15 Av Prof, F-35043 Rennes, France
Araujo, Rafael Rodrigo
Lopez, Juan Guillermo
论文数: 0引用数: 0
h-index: 0
机构:
Sanofi Pasteur, Av Univ 1738, Ciudad De Mexico 04000, Cdmx, MexicoUniv Rennes, Dept Quantitat Methods Publ Hlth, UPRES EA Reperes 7449, EHESP, 15 Av Prof, F-35043 Rennes, France
Lopez, Juan Guillermo
Petitjean, Audrey
论文数: 0引用数: 0
h-index: 0
机构:
Sanofi Pasteur, 14 Espace Henry Vallee, F-69007 Lyon, FranceUniv Rennes, Dept Quantitat Methods Publ Hlth, UPRES EA Reperes 7449, EHESP, 15 Av Prof, F-35043 Rennes, France
Petitjean, Audrey
de Albuquerque Luna, Expedito Jose
论文数: 0引用数: 0
h-index: 0
机构:
Univ Sao Paulo, Inst Trop Med IMT, Av Dr Eneas Carvalho Aguiar,470 Jardim Amer, BR-05403000 Sao Paulo, SP, BrazilUniv Rennes, Dept Quantitat Methods Publ Hlth, UPRES EA Reperes 7449, EHESP, 15 Av Prof, F-35043 Rennes, France
机构:
Chinese Univ Hong Kong, Fac Med, Sch Pharm, Shatin, NT, Peoples R ChinaChinese Univ Hong Kong, Fac Med, Sch Pharm, Shatin, NT, Peoples R China
You, Joyce H. S.
Ming, Wai-kit
论文数: 0引用数: 0
h-index: 0
机构:
Chinese Univ Hong Kong, Fac Med, Sch Pharm, Shatin, NT, Peoples R ChinaChinese Univ Hong Kong, Fac Med, Sch Pharm, Shatin, NT, Peoples R China
Ming, Wai-kit
Chan, Paul K. S.
论文数: 0引用数: 0
h-index: 0
机构:
Chinese Univ Hong Kong, Fac Med, Dept Microbiol, Shatin, NT, Peoples R China
Chinese Univ Hong Kong, Fac Med, Stanley Ho Ctr Emerging Infect Dis, Shatin, NT, Peoples R ChinaChinese Univ Hong Kong, Fac Med, Sch Pharm, Shatin, NT, Peoples R China
机构:
Sanofi, Sao Paulo, SP, BrazilSanofi, Sao Paulo, SP, Brazil
Watanabe, S. F.
Moraes, J. C.
论文数: 0引用数: 0
h-index: 0
机构:
Santa Casa Sao Paulo, Fac Ciencias Med, Sao Paulo, SP, BrazilSanofi, Sao Paulo, SP, Brazil
Moraes, J. C.
Richtmann, R.
论文数: 0引用数: 0
h-index: 0
机构:
Grp Santa Joana, Sao Paulo, SP, BrazilSanofi, Sao Paulo, SP, Brazil
Richtmann, R.
Antonini Ribeiro, R.
论文数: 0引用数: 0
h-index: 0
机构:
Inst Infectol Emilio Ribas, Sao Paulo, SP, Brazil
Natl Inst Sci & Technol Hlth Technol Assessment, Porto Alegre, RS, BrazilSanofi, Sao Paulo, SP, Brazil
Antonini Ribeiro, R.
Galvao, E.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Vales Jequitinhonha & Mucuri, Diamantina, MG, BrazilSanofi, Sao Paulo, SP, Brazil
Galvao, E.
de Courville, C.
论文数: 0引用数: 0
h-index: 0
机构:
Sanofi, Lyon, FranceSanofi, Sao Paulo, SP, Brazil
de Courville, C.
Ribeiro, K.
论文数: 0引用数: 0
h-index: 0
机构:
Sanofi, Sao Paulo, SP, BrazilSanofi, Sao Paulo, SP, Brazil
Ribeiro, K.
Santoro, J.
论文数: 0引用数: 0
h-index: 0
机构:
Sanofi, Sao Paulo, SP, BrazilSanofi, Sao Paulo, SP, Brazil